Archives

  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01

    • Imatinib (STI571): Selective Tyrosine Kinase Inhibition f...

    2025-10-25

    Imatinib (STI571): Selective Tyrosine Kinase Inhibition for Cancer Research

    Executive Summary: Imatinib (STI571) is a selective inhibitor of PDGF receptor, c-Kit, and Abl kinases, with IC50 values of 0.1 μM for PDGFR and c-Kit, and 0.025 μM for Abl, validated in vitro and in cell-based assays (Shapira-Netanelov et al., 2025). Imatinib blocks downstream signaling, including the MAP kinase pathway, thereby inhibiting cell proliferation and tumor growth. The compound’s specificity allows for precise interrogation of tyrosine kinase signaling in both basic and translational research settings. Its performance is stable in DMSO (≥24.68 mg/mL) and ethanol (≥2.48 mg/mL, with ultrasonication), but it is insoluble in water. Recent assembloid models demonstrate that Imatinib’s efficacy is context-dependent, with tumor–stroma interactions modulating response (DOI).

    Biological Rationale

    Tyrosine kinases such as PDGF receptor, c-Kit, and Abl regulate cell proliferation, survival, and migration. Aberrant activation of these kinases is implicated in malignancies and certain nonmalignant proliferative diseases. Selective inhibition enables researchers to dissect specific signaling pathways driving tumorigenesis (Shapira-Netanelov et al., 2025). Imatinib (STI571) was developed to target these kinases with high specificity, minimizing off-target effects and permitting clearer attribution of biological outcomes to kinase inhibition. In cancer, these pathways are often dysregulated, leading to uncontrolled growth and resistance to therapies. Imatinib’s selectivity is especially valuable in complex models such as patient-derived assembloids, where tumor–stroma crosstalk influences drug response (DOI).

    Mechanism of Action of Imatinib (STI571)

    Imatinib (STI571) binds to the ATP-binding site of type 3 receptor tyrosine kinases: PDGF receptor, c-Kit, and Abl. It competitively inhibits kinase phosphorylation activity, preventing downstream signaling such as MAP kinase pathway activation (ApexBio product dossier). By blocking phosphorylation, Imatinib halts the cascade responsible for cell proliferation and tumor growth. The compound demonstrates selectivity, sparing related kinases such as Fms and Flt-3, which reduces unintended biological effects. In vitro, Imatinib inhibits PDGF-AA and PDGF-BB stimulated phosphorylation in Swiss 3T3 cells, and SCF-stimulated tyrosine phosphorylation in MO7e cells, with dose-dependent efficacy. The resulting suppression of MAP kinase and related pathways curtails both malignant and nonmalignant cellular proliferation (Shapira-Netanelov et al., 2025).

    Evidence & Benchmarks

    • Imatinib inhibits PDGF receptor, c-Kit, and Abl kinase activities with IC50 values of 0.1 μM, 0.1 μM, and 0.025 μM, respectively, under cell-free and cell-based assay conditions (ApexBio product dossier).
    • In Swiss 3T3 fibroblast cells, Imatinib blocks PDGF-AA and PDGF-BB-stimulated receptor phosphorylation in a concentration-dependent manner (0.01–1 μM) (Shapira-Netanelov et al., 2025).
    • Imatinib demonstrates high selectivity over Fms and Flt-3 kinases, with negligible inhibition at concentrations up to 10 μM (ApexBio).
    • In patient-derived gastric cancer assembloid models, Imatinib’s efficacy is modulated by the presence of stromal cell subpopulations, highlighting the importance of tumor microenvironment in drug response (DOI).
    • Solubility benchmarks: ≥24.68 mg/mL in DMSO; ≥2.48 mg/mL in ethanol with ultrasonication; insoluble in water (tested at 25°C, standard atmospheric pressure) (ApexBio).
    • For storage, Imatinib should be kept at -20°C; working solutions are stable for short-term use (ApexBio).
    • Recent assembloid research confirms Imatinib’s utility in dissecting resistance mechanisms in personalized cancer models (DOI).

    Applications, Limits & Misconceptions

    Imatinib (STI571) is widely used in research on:

    • Signal transduction pathways in cancer and nonmalignant proliferative diseases.
    • Personalized drug screening in organoid and assembloid models (DOI).
    • Benchmarking kinase selectivity and resistance mechanisms.
    • Elucidating tumor–stroma interactions and microenvironmental modulation of drug response.

    Compared to previous reviews, which focus on classical in vitro models, this article extends the analysis to complex assembloid systems, providing updated insights into microenvironmental effects.

    Unlike the broader overview in this article, which centers on tyrosine kinase pathway mapping, our discussion specifically benchmarks Imatinib’s selectivity and solubility parameters relevant to experimental design.

    Common Pitfalls or Misconceptions

    • Imatinib is not effective against kinases outside the type 3 receptor tyrosine kinase family (e.g., Fms, Flt-3).
    • The compound is insoluble in water; improper solubilization can lead to experimental failure.
    • Short-term solution stability mandates prompt use; long-term stock solutions may degrade at room temperature.
    • Efficacy in assembloid models may not directly translate to monoculture systems due to microenvironmental effects (DOI).
    • Not all tumor types exhibit sensitivity; resistance mechanisms may override kinase inhibition (DOI).

    Workflow Integration & Parameters

    Imatinib (STI571) is supplied as a solid (SKU: B2171) and should be reconstituted in DMSO or ethanol (with ultrasonic treatment for ethanol). Recommended stock concentrations are 10–50 mM. For cell-based assays, typical working concentrations range from 0.01 μM to 10 μM, depending on target sensitivity. All solutions should be prepared fresh or stored at -20°C for short-term stability (ApexBio). For assembloid or organoid drug screening, include appropriate controls to account for microenvironmental modulation. Solubility and stability data are critical for protocol reproducibility. For extended protocol guidance, see this detailed workflow article, which this dossier updates with new microenvironmental considerations.

    Conclusion & Outlook

    Imatinib (STI571) remains a cornerstone in cancer biology and signal transduction research due to its high selectivity, potency, and reproducible performance in diverse models. Its application in emerging assembloid systems enhances the physiological relevance of preclinical studies, supporting the identification of resistance mechanisms and the optimization of personalized therapies (Shapira-Netanelov et al., 2025). For comprehensive product details and ordering, visit the Imatinib (STI571) product page. Ongoing refinements in tumor modeling will further clarify Imatinib’s role in translational oncology and precision medicine.